Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-14 of 14

Sort by

Sort Order Select

Journal Articles

A Multivalent Peptoid Conjugate Modulates Androgen Receptor Transcriptional Activity to Inhibit Therapy-resistant Prostate Cancer

Justine Habault, Jeffrey A. Schneider, Susan Ha, Rachel Ruoff, Luiza D. Pereira, Joseph Puccini, Michela Ranieri, Ruveyda Ayasun, Jiehui Deng, Amanda C. Kasper, Dafna Bar-Sagi, Kwok-Kin Wong, Amina Zoubeidi, Frank Claessens, David R. Wise, Susan K. Logan, Kent Kirshenbaum, Michael J. Garabedian

Mol Cancer Ther (2023) 22 (10): 1166–1181.

https://doi.org/10.1158/1535-7163.MCT-23-0196

Published: 02 October 2023

View article titled, A Multivalent Peptoid Conjugate Modulates Androgen Receptor Transcriptional Activity to Inhibit Therapy-resistant Prostate Cancer

Includes: Supplementary data

Journal Articles

The KRAS^G12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy

David M. Briere, Shuai Li, Andrew Calinisan, Niranjan Sudhakar, Ruth Aranda, Lauren Hargis, David H. Peng, Jiehui Deng, Lars D. Engstrom, Jill Hallin, Sole Gatto, Julio Fernandez-Banet, Adam Pavlicek, Kwok-Kin Wong, James G. Christensen, Peter Olson

Mol Cancer Ther (2021) 20 (6): 975–985.

https://doi.org/10.1158/1535-7163.MCT-20-0462

Published: 01 June 2021

View article titled, The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy

Includes: Supplementary data

Journal Articles

Abstract C75: Overcoming KRAS/LKB1 mutant NSCLC resistance to BET bromodomain inhibitors with gemcitabine or Mcl-1 inhibition

Michael Kahle, Margaret Soucheray, Jeffrey Becker, Eiki Kikuchi, Inés Pulido, Esra Akbay, Camilla Christensen, Wei Qiu, Fatima Al-Shahrour, Neil Johnson, Julián Carretero, Kwok-Kin Wong, Takeshi Shimamura

Mol Cancer Ther (2015) 14 (12_Supplement_2): C75.

https://doi.org/10.1158/1535-7163.TARG-15-C75

Published: 01 December 2015

View article titled, Abstract C75: Overcoming KRAS/LKB1 mutant NSCLC resistance to BET bromodomain inhibitors with gemcitabine or Mcl-1 inhibition

Journal Articles

Abstract B96: Adaptive resistance to therapeutic PD-1:PD-L1 blockade is mediated by upregulation of the TIM-3 immune checkpoint

Mol Cancer Ther (2015) 14 (12_Supplement_2): B96.

https://doi.org/10.1158/1535-7163.TARG-15-B96

Published: 01 December 2015

View article titled, Abstract B96: Adaptive resistance to therapeutic PD-1:PD-L1 blockade is mediated by upregulation of the TIM-3 immune checkpoint

Journal Articles

Abstract B99: Immune profiling of NSCLC tumors and matching normal lung samples by multicolor flow cytometry

Elena Ivanova, Robert E. Jones, Mark M. Awad, Mark A. Bittinger, Meghana M. Kulkarni, Shohei Koyama, Christina G. Almonte, Abigail A. Santos, Jessie M. English, Julianne Barlow, William G. Richards, Peter S. Hammerman, Scott J. Rodig, Raphael Bueno, Kwok-Kin Wong

Mol Cancer Ther (2015) 14 (12_Supplement_2): B99.

https://doi.org/10.1158/1535-7163.TARG-15-B99

Published: 01 December 2015

View article titled, Abstract B99: Immune profiling of NSCLC tumors and matching normal lung samples by multicolor flow cytometry

Journal Articles

Abstract A69: An epigenetic-focused CRISPR/Cas9 screen to identify regulators of IFNγ-induced PD-L1 expression

Troy A. Luster, Meghana Kulkarni, Erica Fitzpatrick, Lauren Badalucco, Jessie English, Kwok-Kin Wong, Mark Bittinger

Mol Cancer Ther (2015) 14 (12_Supplement_2): A69.

https://doi.org/10.1158/1535-7163.TARG-15-A69

Published: 01 December 2015

View article titled, Abstract A69: An epigenetic-focused CRISPR/Cas9 screen to identify regulators of IFNγ-induced PD-L1 expression

Journal Articles

Abstract LB-C21: CXCR7 expression is necessary for the maintenance of mesenchymal phenotype in acquired EGFR TKI resistance in NSCLC

Jeffrey H. Becker, Yandi Gao, Ines Pulido, Eiki Kikuchi, Margaret Soucheray, Rutu Gandhi, Camilla L. Christensen, Fatima Al-shahrour, Kwok-Kin Wong, Julian Carretero, Takeshi Shimamura

Mol Cancer Ther (2015) 14 (12_Supplement_2): LB-C21.

https://doi.org/10.1158/1535-7163.TARG-15-LB-C21

Published: 01 December 2015

View article titled, Abstract LB-C21: CXCR7 expression is necessary for the maintenance of mesenchymal phenotype in acquired EGFR TKI resistance in NSCLC

Journal Articles

NSCLC Driven by DDR2 Mutation Is Sensitive to Dasatinib and JQ1 Combination Therapy

Chunxiao Xu, Kevin A. Buczkowski, Yanxi Zhang, Hajime Asahina, Ellen M. Beauchamp, Hideki Terai, Yvonne Y. Li, Matthew Meyerson, Kwok-kin Wong, Peter S. Hammerman

Mol Cancer Ther (2015) 14 (10): 2382–2389.

https://doi.org/10.1158/1535-7163.MCT-15-0077

Published: 05 October 2015

View article titled, NSCLC Driven by DDR2 Mutation Is Sensitive to Dasatinib and JQ1 Combination Therapy

Includes: Supplementary data

Journal Articles

Abstract PR09: Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS-mutant cancer models

Mol Cancer Ther (2013) 12 (5_Supplement): PR09.

https://doi.org/10.1158/1535-7163.PMS-PR09

Published: 01 May 2014

View article titled, Abstract PR09: Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS-mutant cancer models

Journal Articles

Acquired Resistance to Dasatinib in Lung Cancer Cell Lines Conferred by DDR2 Gatekeeper Mutation and NF1 Loss

Ellen M. Beauchamp, Brittany A. Woods, Austin M. Dulak, Li Tan, Chunxiao Xu, Nathanael S. Gray, Adam J. Bass, Kwok-kin Wong, Matthew Meyerson, Peter S. Hammerman

Mol Cancer Ther (2014) 13 (2): 475–482.

https://doi.org/10.1158/1535-7163.MCT-13-0817

Published: 09 February 2014

View article titled, Acquired Resistance to Dasatinib in Lung Cancer Cell Lines Conferred by DDR2 Gatekeeper Mutation and NF1 Loss

Includes: Supplementary data

Journal Articles

Abstract B290: Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.

Esra A. Akbay, Shohei Koyama, Julian Carretero, Abigail Altabef, Jeremy Tchaicha, Camilla Christensen, Takeshi Shimamura, Lynette Sholl, Scott Rodig, Gordon Freeman, Peter Hammerman, Glenn Dranoff, Kwok-Kin Wong

Mol Cancer Ther (2013) 12 (11_Supplement): B290.

https://doi.org/10.1158/1535-7163.TARG-13-B290

Published: 01 November 2013

View article titled, Abstract B290: Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.

Journal Articles

Abstract A177: Cetuximab resistance associated with dimerization‐independence of oncogenic EGFR mutants

Jeonghee Cho, Liang Chen, Naveen Sangji, Jinyan Du, Takafumi Okabe, Kimio Yonesaka, Joshua M. Francis, Richard J. Flavin, Soyoung Yu, Heidi E. Greulich, Bruce E. Johnson, Michael J. Eck, Pasi A. Jänne, Kwok‐Kin Wong, Matthew Meyerson

Mol Cancer Ther (2009) 8 (12_Supplement): A177.

https://doi.org/10.1158/1535-7163.TARG-09-A177

Published: 10 December 2009

View article titled, Abstract A177: Cetuximab resistance associated with dimerization‐independence of oncogenic EGFR mutants

Journal Articles

Abstract A199: Oncogenic and drug‐sensitive ERBB2 mutations in glioblastoma

Heidi Greulich, Milan Chheda, Tzu‐Hsiu Chen, Kumiko Tanaka, Amit Dutt, Kwok‐Kin Wong, William Hahn, Matthew Meyerson

Mol Cancer Ther (2009) 8 (12_Supplement): A199.

https://doi.org/10.1158/1535-7163.TARG-09-A199

Published: 10 December 2009

View article titled, Abstract A199: Oncogenic and drug‐sensitive ERBB2 mutations in glioblastoma

Journal Articles

Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancer

Marcus M. Schittenhelm, Christian Kollmannsberger, Karin Oechsle, Amy Harlow, Jason Morich, Friedemann Honecker, Raffael Kurek, Stephan Störkel, Lothar Kanz, Christopher L. Corless, Kwok-Kin Wong, Carsten Bokemeyer, Michael C. Heinrich

Mol Cancer Ther (2009) 8 (3): 481–489.

https://doi.org/10.1158/1535-7163.MCT-08-1068

Published: 13 March 2009

View article titled, Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancer

NARROW

A Multivalent Peptoid Conjugate Modulates Androgen Receptor Transcriptional Activity to Inhibit Therapy-resistant Prostate Cancer

The KRAS^G12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy

Abstract C75: Overcoming KRAS/LKB1 mutant NSCLC resistance to BET bromodomain inhibitors with gemcitabine or Mcl-1 inhibition

Abstract B96: Adaptive resistance to therapeutic PD-1:PD-L1 blockade is mediated by upregulation of the TIM-3 immune checkpoint

Abstract B99: Immune profiling of NSCLC tumors and matching normal lung samples by multicolor flow cytometry

Abstract A69: An epigenetic-focused CRISPR/Cas9 screen to identify regulators of IFNγ-induced PD-L1 expression

Abstract LB-C21: CXCR7 expression is necessary for the maintenance of mesenchymal phenotype in acquired EGFR TKI resistance in NSCLC

NSCLC Driven by DDR2 Mutation Is Sensitive to Dasatinib and JQ1 Combination Therapy

Abstract PR09: Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS-mutant cancer models

Acquired Resistance to Dasatinib in Lung Cancer Cell Lines Conferred by DDR2 Gatekeeper Mutation and NF1 Loss

Abstract B290: Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.

Abstract A177: Cetuximab resistance associated with dimerization‐independence of oncogenic EGFR mutants

Abstract A199: Oncogenic and drug‐sensitive ERBB2 mutations in glioblastoma

Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancer

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only